June 12, 2026
Matthew Pennell, Christine Freer, James Bennett–levy et al.
preprint
Psychedelic-assisted therapy (PAT) is moving from research settings towards broader implementation. During this transition, the therapist role is being formalised before the developmental pathways into the role are well understood. Existing clinicians are being selected, trained, and authorised to practise in a field marked by an emergent knowledge base and the convergence of multiple cultural...
Drugs Education Prevention and Policy
March 22, 2026
Jordan J. Negrine, Stephen Bright, Monica J Barratt et al.
Background Following Australia’s landmark 2023 decision to approve psilocybin and MDMA for clinical use, psychedelic-assisted therapy (PAT) is beginning to emerge within regulated mental health settings. This study investigates psychologists’ views on the relevance of psychedelic therapists’ lived-living experience (LLE) with psychedelics. While discussion around LLE is growing, little is known...
BMJ Open
April 1, 2025
Vanessa L. Beesley, Tom Kennedy, Fiona Maccallum et al.
2 citations
Introduction Prolonged grief disorder (PGD) represents a substantial public health issue, especially in oncology settings where it affects up to 30% of bereaved carers. Current best-practice treatments are lengthy, and up to 50% of participants have persistent PGD. Building on encouraging recent research with psychedelic-assisted therapies, the Psilocybin-Assisted suppoRtive psychoTherapy IN...
Frontiers in Psychiatry
November 4, 2021
M.l. Williams, Diana Korevaar, Renee Harvey et al.
23 citations
Research exploring the potential of psychedelic-assisted therapies to treat a range of mental illnesses is flourishing, after the problematic sociopolitical history of psychedelics led to the shutdown of clinical research for almost 40 years. Encouraged by positive results, clinicians and patients are now hopeful that further interruptions to research will be avoided, so that the early promise...